Get the Stockscreener App
2.72
3.82%
0.10
After Hours:
2.74
0.02
+0.74%
Iovance Biotherapeutics Inc stock is traded at $2.72, with a volume of 7.03M.
It is up +3.82% in the last 24 hours and up +15.25% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.62
Open:
$2.62
24h Volume:
7.03M
Relative Volume:
0.63
Market Cap:
$1.08B
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-2.2114
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
+4.62%
1M Performance:
+15.25%
6M Performance:
+8.80%
1Y Performance:
-51.08%
1-Day Range:
$2.60
$2.76
1-Week Range:
$2.465
$2.76
52-Week Range:
$1.6385
$6.09
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.72 | 1.04B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.31 | 121.26B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
792.16 | 83.89B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
845.35 | 52.20B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
332.68 | 44.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
359.05 | 39.27B | 4.98B | 69.60M | 525.67M | 0.5198 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
Stock Market Today, Feb. 18: ImmunityBio Soars After EU Approves ANKTIVA for Bladder Cancer - The Motley Fool
Aug Technicals: Is Iovance Biotherapeutics Inc likely to announce a buybackGap Up & Weekly Top Performers Watchlists - baoquankhu1.vn
Loss Report: Can Elme Communities be recession proofPortfolio Risk Report & Fast Gain Stock Tips - baoquankhu1.vn
Iovance Biotherapeutics Inc. (IOVA) Builds Momentum With New Trial Data - Insider Monkey
US Market Wrap: Is Iovance Biotherapeutics Inc being accumulated by smart money2025 Year in Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Published on: 2026-02-16 00:19:11 - mfd.ru
Principal Financial Group Inc. Has $6.54 Million Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Is Iovance Biotherapeutics Inc. stock resilient to inflationJuly 2025 Short Interest & AI Forecasted Entry/Exit Points - mfd.ru
Iovance Biotherapeutics Inc. (IOVA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Iovance Biotherapeutics, Inc. (IOVA): A 261% Potential Upside Sparks Investor Interest - DirectorsTalk Interviews
Can Iovance Biotherapeutics Inc. stock double in the next yearInflation Watch & Fast Moving Market Watchlists - mfd.ru
April 2nd Options Now Available For Iovance Biotherapeutics (IOVA) - Nasdaq
Will Iovance Biotherapeutics Inc. stock go up in YEARTrade Risk Report & Breakout Confirmation Alerts - mfd.ru
Can Iovance Biotherapeutics Inc grow without dilutionJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Updates on Tuesday, February 24, 2026 - The Manila Times
Iovance Biotherapeutics to Host Conference Call for Q4 and Full Year 2025 Financial Results on February 24, 2026 - Quiver Quantitative
Iovance Biotherapeutics to Report Fourth Quarter and Full - GlobeNewswire
Is Iovance Biotherapeutics Inc. stock a contrarian buyWeekly Trade Recap & Free Risk Controlled Daily Trade Plans - mfd.ru
What’s the beta of Iovance Biotherapeutics Inc. stockPortfolio Gains Summary & Free AI Powered Buy and Sell Recommendations - mfd.ru
The Bull Case For Iovance Biotherapeutics (IOVA) Could Change Following New Amtagvi Real-World DataLearn Why - Sahm
Market Wrap: Will Iovance Biotherapeutics Inc benefit from green energy policiesCPI Data & Expert Curated Trade Setups - baoquankhu1.vn
Assessing Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Volatility - Yahoo Finance
Is It Time To Reconsider Iovance Biotherapeutics (IOVA) After Prolonged Share Price Weakness - Yahoo Finance
Iovance’s Amtagvi Data and Valuation Gap Refocus Investor Attention - Yahoo Finance
Does The Recent Share Price Slump Make Iovance Biotherapeutics (IOVA) Look More Attractive? - Sahm
Iovance Biotherapeutics (IOVA) Gives Update on Revenue Guidance, Lung Cancer Cure - Insider Monkey
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Melanoma cell therapy shows 52% response when used earlier - stocktitan.net
Iovance Biotherapeutics Announces Promising Real-World Data for Amtagvi® in Advanced Melanoma Treatment - Quiver Quantitative
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Assessing Iovance Biotherapeutics (IOVA) Valuation As It Transitions To Commercial Stage With First Product Launch Plans - Sahm
Iovance down 18% warning it could be impacted by geopolitical instability, inflation - MSN
Former Iovance CEO Maria Fardis lands at AirNexis with $200 millionBizwomen - The Business Journals
She raised more than $1 billion for Iovance. Now, Maria Fardis has a new startup and a $200 million investment - The Business Journals
Performance Recap: Why is Iovance Biotherapeutics Inc stock going upJuly 2025 Opening Moves & Capital Efficiency Focused Strategies - baoquankhu1.vn
Trade Recap: Whats the beta of Iovance Biotherapeutics Inc stockOptions Play & Real-Time Sentiment Analysis - baoquankhu1.vn
Iovance Biotherapeutics (IOVA): Investor Outlook Reveals 217% Potential Upside - DirectorsTalk Interviews
Aug Reactions: Will Iovance Biotherapeutics Inc benefit from AI trendsJobs Report & Target Return Focused Stock Picks - baoquankhu1.vn
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates - GuruFocus
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.5%Should You Sell? - MarketBeat
Financial Investigation Sparks Potential Reforms at Iovance Biotherapeutics - StocksToTrade
Is Iovance Biotherapeutics Inc. showing insider buyingJuly 2025 Drop Watch & Low Risk Profit Maximizing Plans - mfd.ru
Activity Recap: Whats the beta of Iovance Biotherapeutics Inc stock2025 Historical Comparison & Real-Time Market Sentiment Alerts - baoquankhu1.vn
Recap Report: Whats the beta of Iovance Biotherapeutics Inc stockGap Up & Risk Controlled Daily Trade Plans - baoquankhu1.vn
Iovance Biotherapeutics (NASDAQ:IOVA) Trading 7.4% HigherStill a Buy? - MarketBeat
IOVA Shares Jump 8% — What’s Retail Expecting? - Stocktwits
Iovance Biotherapeutics Sets Stage for Global TIL Leadership with Stock Induction Moves - StocksToTrade
Short Squeeze: Can LANDP sustain its profitability2025 Risk Factors & Verified Short-Term Plans - baoquankhu1.vn
Iovance Biotherapeutics, Inc. (IOVA) Stock Analysis: Unpacking a Potential 210% Upside Amidst Biotech Innovations - DirectorsTalk Interviews
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Is Expected To Breakeven In The Near Future - 富途牛牛
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):